Why Amazon’s Stock Isn’t as Great as You Think
For CFOs wanting to understand investor behavior, here's an argument that Jeff Bezos is human, after all, and Amazon can't defy basic economic principles.
Mylan Underpaid U.S. on Rebates for EpiPen
A federal official says the drugmaker misclassified EpiPen, possibly costing Medicaid millions of dollars in rebates.
Merck Buys Cough Drug Developer for $1.25B
The acquisition of Afferent Pharmaceuticals gives Merck access to a drug candidate for treating neurogenic conditions including chronic cough.
Pfizer Adds Eczema Gel With $5B Anacor Deal
If Anacor's treatment for eczema is approved by the FDA, Pfizer predicts peak-year sales could exceed $2 billion.
Biotech CFO Accused of Misleading Investors
The ex-CFO of Aveo Pharmaceuticals and other top executives allegedly failed to disclose FDA concerns about an experimental cancer drug.
Ireland’s Shire Buys Baxalta for $32 Billion
The drug maker says the deal will further its goal of "building the leading biotechnology company focused on rare diseases."
Valeant Stock Falls 10% on News of CEO’s Illness
Michael Pearson, who was hospitalized with pneumonia, has been trying to win back investor trust amid concerns over Valeant's pricing practices.
Novartis Settles Kickback Charges for $370M
The Swiss drug maker allegedly turned specialty pharmacies into a "biased sales force" for its medications.
Shire to Buy Rival Drug Maker Dyax for $5.9B
The deal gives the acquisitive Irish company access to an experimental drug that competes with its own treatment for a rare disease.
Cipla Buys Two U.S. Pharma Firms for $550M
The acquisitions give the Indian drug maker its first manufacturing plant in the U.S. and an opportunity to build U.S. market share.